casirivimab/imdevimab (Ronapreve) - versus control - for COVID 19 outpatients pdf   xlsx method abbreviations

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

deaths 0.54 [0.08, 3.54]< 10%2 studies (2/-)74.0 %some concernnot evaluable moderatecrucial-
hospitalization or death 0.29 [0.12, 0.68]< 10%1 study (1/-)99.8 %some concernnot evaluable moderatecrucial-
hospitalization 0.08 [0.00, 1.49]< 10%1 study (1/-)95.3 %some concernnot evaluable moderateimportant-
symptomatic Covid-19 0.56 [0.31, 1.00]< 10%1 study (1/-)97.6 %some concernnot evaluable moderateimportant-

safety endpoints 00

serious adverse events 0.25 [0.03, 2.23]< 10%1 study (1/-)89.2 %some concernnot evaluable moderateimportant-
adverse events 0.55 [0.34, 0.86]< 10%1 study (1/-)99.5 %some concernnot evaluable moderatenon important-

LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias; suggested: nominally statistically significant but without a strict control of overall risk of type 1 error; inconclusive: not nominally statistically significant; safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.